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Mg2+We demonstrated a role for the Mg2+ transporter TRPM7, a bifunctional protein with channel and α-kinase
domains, in aldosterone signaling. Molecular mechanisms underlying this are elusive. Here we investigated
the function of TRPM7 and its α-kinase domain on Mg2+ and pro-inﬂammatory signaling by aldosterone.
Kidney cells (HEK-293) expressing wild-type human TRPM7 (WThTRPM7) or constructs in which the
α-kinase domain was deleted (ΔKinase) or rendered inactive with a point mutation in the ATP binding site
of the α-kinase domain (K1648R) were studied. Aldosterone rapidly increased [Mg2+]i and stimulated
NADPH oxidase-derived generation of reactive oxygen species (ROS) in WT hTRPM7 and TRPM7 kinase
dead mutant cells. Translocation of annexin-1 and calpain-II and spectrin cleavage (calpain target) were in-
creased by aldosterone in WT hTRPM7 cells but not in α-kinase-deﬁcient cells. Aldosterone stimulated phos-
phorylation of MAP kinases and increased expression of pro-inﬂammatory mediators ICAM-1, Cox-2 and
PAI-1 in Δkinase and K1648R cells, effects that were inhibited by eplerenone (mineralocorticoid receptor
(MR) blocker). 2-APB, a TRPM7 channel inhibitor, abrogated aldosterone-induced Mg2+ responses in WT
hTRPM7 and mutant cells. In 2-APB-treated ΔKinase and K1648R cells, aldosterone-stimulated inﬂammatory
responses were unchanged. These data indicate that aldosterone stimulates Mg2+ inﬂux and ROS production
in a TRPM7-sensitive, kinase-insensitive manner, whereas activation of annexin-1 requires the TRPM7 kinase
domain. Moreover TRPM7 α-kinase modulates inﬂammatory signaling by aldosterone in a TRPM7 channel/
Mg2+-independent manner. Our ﬁndings identify novel mechanisms for non-genomic actions of aldosterone
involving differential signaling through MR-activated TRPM7 channel and α-kinase.
© 2013 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Aldosterone, a steroid hormone with mineralocorticoid activity, is
typically associatedwith volume homeostasis and blood pressure regu-
lation through its effects on renal Na+ reabsorption and K+ secretion
[1]. Aldosterone also controls renal handling of other ions, including
Mg2+ [2]. Hyperaldosteronism leads to renal K+ and Mg2+ wasting
with associated cardiovascular injury and ﬁbrosis. In addition to regu-
lating renal ion transport through mineralocorticoid receptor (MR) ge-
nomic signaling, aldosterone inﬂuences non-classical including tissueerms of the Creative Commons
which permits non-commercial
d theoriginal author and source
Medical Sciences, BHFGlasgow
6 University Place, Glasgow G12
3360.
uyz).
blished by Elsevier Inc. All rights reremodeling, inﬂammation and ﬁbrosis [3–5]. Recent evidence suggests
that these effects are mediated by MR and decreased [Mg2+]i since
spironolactone and eplerenone (MR antagonists) as well as Mg2+ ad-
ministration, ameliorate these processes [6,7]. At the sub-cellular level
Mg2+ regulates protein phosphorylation, modulates ion transport and
is a cofactor for many enzymes [8]. Moreover, through Mg2+-sensitive
mitogen-activated protein (MAP) kinases, tyrosine kinases and reactive
oxygen species (ROS), Mg2+ regulates signaling pathways associated
with inﬂammation and ﬁbrosis [8,9].
Molecular mechanisms whereby aldosterone controls cellular
Mg2+ and its associated signaling pathways are unclear, but transient
receptor potential melastatin cation channel 7 (TRPM7), has been im-
plicated [10,11]. TRPM7 belongs to the TRP ion channel superfamily
and has a distinctive ion permeability proﬁle, allowing Mg2+ and
other divalent cations to comprise its inward current [12,13]. Similar
to its homologue TRPM6, it has the unique feature of an α-kinase do-
main at its carboxy-terminal and has channel-enzyme bifunctionality
activity [10–14], hence referred to as a “chanzyme” [15]. A number ofserved.
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including: annexin-1, m-calpain, myosin IIA heavy chain and elonga-
tion factor 2 (eEF2) [16–18]. In addition, PLCγ2 is phosphorylated by
the Ser/Thr kinase domain of TRPM7 [19]. TRPM7 has an essential and
non-redundant function in cell growth and development because
TRPM7-deﬁcient cells die and Trpm7−/− mouse embryos do not sur-
vive past day 7 of embryogenesis [20,21].
The C-terminal kinase is homologous to α-kinases, atypical ser-
ine–threonine kinases, and structurally resembles protein kinase A.
The functional relationship between the channel and kinase domains
is unclear and there is conﬂicting data whether TRPM7 kinase signal-
ing is essential for TRPM7 channel activity. Early studies suggested
that the channel function depends on the α-kinase domain [22,23],
although more recent data suggest that TRPM7 α-kinase is not essen-
tial for activation of the channel [12]. TRPM7 channel regulation in-
volves phosphorylation of at least 14 sites in the cytoplasmic
domain, as demonstrated in a stable cell line expressing mouse
TRPM7 [24]. Although many factors, including aldosterone, inﬂuence
TRPM7 function [25–27], the exact molecular processes remain un-
known and it is unclear whether TRPM7 channel function and/or
TRPM7 α-kinase activity is involved in aldosterone signaling.
To better understand these processes, we investigated the role of
TRPM7 and its α-kinase domain in non-genomic signaling by aldoste-
rone, focusing on Mg2+ transport and proinﬂammatory responses, by
studying kidney cells (HEK-293) expressing wild-type human TRPM7
(WT hTRPM7) or constructs in which the α-kinase domain has been
deleted (ΔKinase) or rendered inactive with a point mutation in the
ATP binding site of the α-kinase domain (K1648R).2. Methods
2.1. Expression of wild-type human TRPM7 and mutant constructs in
HEK-293 cells
WT hTRPM7, Δkinase and K1648R cDNA cloning and expression in
HEK-293 T-Rex cells (Invitrogen) have been previously described
[28]. HEK-293 cells were transfected with a pcDNA4/TO plasmid
that allowed tetracycline-inducible protein expression of WT
hTRPM7 and hTRPM7 mutants for the α-kinase deletion or lacking
of phosphotransferase activity. Protein expression was induced
using tetracycline-controlled transcription (1 μg/ml).2.2. Cell stimulation protocols
HEK-293 cells were induced for 48 h, and rendered quiescent in
serum-free DMEM supplemented with tetracycline for 24 h. Growth-
arrested cells were stimulated with 100 nmol/L aldosterone for short
(1 to 60 min) or long (4 to 24 h) periods of time to examine non-
genomic (acute) and genomic effects respectively. In some experiments
cells were pre-exposed for 30 min to 50 μM 2-Aminoethoxydiphenyl
borate (2-APB) (TRPM7 inhibitor), 10 μM eplerenone (MR antagonist),
or 10 μM mifepristone (GR antagonist). Concentrations of inhibitors
used were based on previously published data [5,27].2.3. Fluorescence measurement of Mg2+
Mg2+ inﬂux was assessed with Mag-Fura-2AM ﬂuorescence dual
excitation wavelength as previously described [29]. Basal measure-
ments were recorded in non-stimulated cells, and following 100 nM
aldosterone stimulation using the Stallion Digital Hi-Speed Multi-
Channel Imaging System (Zeiss, Germany). The emission wavelength
was 520 nm, with alternating excitatory wavelengths of 340 and
380 nm. Results were expressed as the ratio of ﬂuorescence acquired
with excitation at 340 and 380 nm.2.4. Immunoblotting
Proteins from cell homogenates were separated by electrophoresis
on a polyacrylamide gel and transferred onto a nitrocellulose mem-
brane as previously described [11]. Membranes were then incubated
with speciﬁc antibodies overnight at 4 °C. Antibodies were as follows:
anti-p38MAPK [Thr180/Tyr182], anti-ERK1/2MAPK [Thr202/Tyr204],
anti-SAPK/JNK [Thr183/Tyr185] (Cell Signaling), anti- intercellular adhe-
sion molecule 1 (ICAM-1), anti- plasminogen activator inhibitor 1
(PAI-1), anti-mineralocorticoid receptor (MR), anti-glucocorticoid re-
ceptor (GR), anti-spectrin (Santa Cruz Biotechnology, Inc), and anti-
cyclooxygenase 2 (Cox-2, Cayman). Anti-GAPDH and antibodies to non
phosphoproteins were used as loading controls and were carried out
on the same membranes for phosphorylated proteins. After incubation
with secondary antibodies, signals were revealed with chemilumines-
cence, visualized by autoradiography and quantiﬁed densitometrically.
2.5. Cytosol-membrane fractionation
Translocation of annexin-1, calpain-II and p47phox (cytosloc
subunit of nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase) from the cytosol to the membrane was assessed in
HEK-293 cells expressing WT hTRPM7 and the mutants. Cells were
lysed and partitioned to obtain cytosol- and membrane-enriched
fractions. Western blotting was performed as described using
anti-annexin-1, anti-calpain-II and anti-p47phox antibodies (Santa
Cruz Biotechnology, Inc). Translocation was determined as the ratio
of protein expression in membrane to cytosolic fractions.
2.6. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
activity
NADPH-mediated ROS generation was measured in cell homoge-
nates by lucigenin-derived chemiluminescence.
2.7. Measurement of ROS with dihydroethidium (DHE) staining
Intracellular generation of ROS was evaluated using the superox-
ide anion-sensitive dye DHE.
2.8. Statistical analysis
Values are shown as means ± S.E. Group differences were evalu-
ated by one-way analysis of variance (ANOVA) followed by the
Dunnett post-test. Differences between mean values were considered
statistically signiﬁcant at pb0.05.
3. Results
3.1. Expression of TRPM7 WT and of TRPM7 kinase dead mutant in HEK
cells
HEK-293 cells possess endogenous TRPM7, which is expressed at
low levels (Fig. 1A). To amplify TRPM7 expression, we expressed
TRPM7 and TRPM7 mutants using tetracycline-controlled transcrip-
tion. After the addition of tetracycline, optimal protein expression
levels of WT hTRPM7 and the kinase dead mutants, ΔKinase and
K1648R, were observed after 48 h and sustained for 72 h (Fig. 1A).
3.2. Endogenous expression of mineralocorticoid and glucocorticoid
receptors in HEK cells
The presence of endogenous MR was detected in HEK-293 cells,
with no changes in the receptor protein expression after tetracycline
treatment (Fig. 1B). Aldosterone has also been shown to bind to glu-
cocorticoid receptor (GR), albeit with much lower afﬁnity. In our
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its protein content was not altered by tetracycline (Fig. 1C).3.3. Aldosterone-induced Mg2+ inﬂux is similar in cells expressing
human TRPM7 and TRPM7 α-kinase mutant
Fig. 2 shows that WT hTRPM7 and the mutants display similar
basal [Mg2+]i. Aldosterone induced an increase in Mag-FURA-2 ﬂuo-
rescence ratio with similar magnitude in HEK-293 cells expressing
WT hTRPM7, Δkinase, and K1648R channels (Fig. 2A). Eplerenone re-
duced aldosterone-induced Mg2+ inﬂux in HEK-293 cells expressing
WT hTRPM7, Δkinase and K1648R channels (Fig. 2B). 2-APB inhibited
aldosterone-mediated [Mg2+]i effects (supplemental Fig. S1).
Aldosterone-stimulated rise in [Mg2+]i was lower in non-induced
versus induced HEK-293 cells (supplemental Fig. S2).3.4. Deletion or mutation in the TRPM7 α-kinase domain does not affect
aldosterone-induced NADPH oxidase activation and ROS generation
In WT hTRPM7, Δkinase and K1648R cells aldosterone increased
ROS generation as assessed by DHE ﬂuorescence and lucigenin chemi-
luminescence with a similar magnitude of change (Figs. 3A, 3B).
These effects were associated with an increase in p47phox transloca-
tion, an index of NADPH oxidase activity, in aldosterone-stimulated
HEK-293 cells overexpressing WT hTRPM7, Δkinase or K1648R
mutants (Fig. 3C). Aldosterone failed to induce a signiﬁcant ROS re-
sponse in cells that were not exposed to tetracycline (supplemental
Figs. S3A–S3C).3.5. Aldosterone-induced annexin-1 and calpain-II translocation to the
cell membrane is blunted in cells expressing hTRPM7 α-kinase mutants
To explore the function of TRPM7α-kinase domain, we investigated
whether aldosterone induces activation of its well known downstream
targets, annexin-1 and calpain-II. These proteins are predominantly lo-
cated in the cytosol and upon activation translocate to the plasmamem-
brane. To monitor the dynamic changes in the cellular distribution of
annexin-1 and calpain-II after aldosterone stimulation, cell lysates
were partitioned into membrane and cytosol-enriched fractions.
Fig. 4A shows that aldosterone induces an increase of annexin-1 content
in themembrane fraction ofWThTRPM7 cells, an effect that is rapid and
transient, since the translocation peak was obtained within 5 min
returning to basal levels after 30 min. In Δkinase and K1648R mutants,
aldosterone failed to stimulate annexin-1 translocation. Long-term
aldosterone stimulation did not elicit annexin-1 translocation in WT
hTRPM7, Δkinase or K1648R cells (Fig. 4B). Unlike annexin-1,
calpain-II did not translocate to the membrane upon aldosterone
short term stimulation (Fig. 4C) in WT hTRPM7, whereas with
long-term stimulation (Fig. 4D) the calpain-II content was increased
in membrane fractions of these cells. Aldosterone had no effect on
calpain-II translocation in Δkinase and K1648R hTRPM7 expressing
cells at any stimulation time point. Aldosterone-induced annexin-1
and calpain-II translocation to the cell membrane was associated with
WT hTRPM7 expression, since no effects were observed in non-
induced cells (supplemental Figs. S4A, S4B). Spectrin, a cytoskeletal
protein, exhibits high sensitivity to calpain proteolytic activity [30]
and hence spectrin cleaved fragment is used as an index of calpain ac-
tivity. We found that aldosterone induced a progressive increase in
the cleaved spectrin fragment in HEK-293 cells expressing WT
hTRPM7 but not in those expressing Δkinase and K1648R mutants
(Fig. 5A). This effect was inhibited by eplerenone in WT hTRPM7 cells
(Fig. 5B). Spectrin cleavage by aldosteronewas not observed in tetracy-
cline untreated cells (supplemental Fig. S4C).3.6. Aldosterone-induced MAPK phosphorylation in cells expressing
TRPM7 α-kinase mutants
To investigate the potential TRPM7 α-kinase-dependent mecha-
nisms by which aldosterone mediates proinﬂammatory events, the
phosphorylation status of p38MAPK, SAPK/JNK, and ERK1/2 was stud-
ied in HEK-293 cells overexpressing WT hTRPM7, Δkinase or K1648R
mutants. As shown in Fig. 6A, aldosterone stimulation resulted in a
rapid and sustained increase of p38MAPK phosphorylation in cells ex-
pressing Δkinase and K1648R mutants. Similar effects were observed
for SAPK/JNK (Fig. 6B) and ERK1/2 (Fig. 6C). No signiﬁcant effects
of aldosterone on MAPK phosphorylation were observed in WT
hTRPM7 cells. In the presence of eplerenone, aldosterone failed to in-
duce p38MAPK, SAPK/JNK and ERK1/2 phosphorylation in mutant
cells (supplemental Fig. S5A–S5C). Aldosterone did not increase
MAPK phosphorylation in cells that were not exposed to tetracycline
(supplemental Fig. S6).
3.7. Expression of inﬂammatory markers in cells expressing TRPM7
α-kinase mutants
Aldosterone stimulation increased expression of ICAM-1(Fig. 7A),
Cox-2 (Fig. 7B), and PAI-1 (Fig. 7C) in Δkinase and K1648R mutants
but not in WT hTRPM-7 cells. Eplerenone prevented these effects
(supplemental Figs. S7A–S7C). Aldosterone had no signiﬁcant effect
on ICAM-1, Cox-2 or PAI-1 in tetracycline-untreated cells (supple-
mental Fig. S8).
3.8. 2-APB effects on aldosterone-induced pro-inﬂammatory responses
To evaluate whether inhibition of TRPM7 channel inﬂuences
aldosterone-induced inﬂammatory responses, cells were pre-exposed
to 2-APB, which we and others have shown to inhibit TRPM7 channel
activity [27,30]. As shown in Figs. 8 and 9, in 2-APB-treated WT
hTRPM-7 cells, aldosterone-induced activation of p38MAP kinase and
JNK was augmented, responses that were associated with upregulation
of pro-inﬂammatory proteins Cox-2 and ICAM-1. In Δkinase and
K1648R mutants, in which aldosterone stimulated activation of
MAP kinases and increased expression of pro-inﬂammatory proteins,
2-APB pre-treatment did not alter aldosterone-induced responses
(Figs. 8B–F, 9B–F)).
4. Discussion
In the present study we have uncovered novel TRPM7-mediated
aldosterone signaling pathways in renal cells. Major ﬁndings demon-
strate that: 1) aldosterone, through MR-dependent mechanisms, rap-
idly stimulates TRPM7-mediated Mg2+ inﬂux; 2) Mg2+ transport and
activation of NADPH oxidase by aldosterone are TRPM7 α-kinase-
independent, whereas calpain and annexin-1 signaling are TRPM7
α-kinase-dependent, and 3) deﬁciency of TRPM7 phosphotransferase
activity or absence of TRPM7α-kinase domain is associated with MAP
kinase activation and pro-inﬂammatory responses by aldosterone.
Our ﬁndings indicate that aldosterone signaling is differentially
regulated by TRPM7 and TRPM7 α-kinase. We identify new discrete
signaling pathways through TRPM7/TRPM7 α-kinase by aldosterone/
MR and indicate a disconnect between TRPM7 channel and α-kinase.
Such processes involve, in part, non-genomic rapid signaling events.
Renal cells represent an excellent model to interrogate aldoste-
rone and TRPM7 signaling because they endogenously express MRs
and TRPM7 and associated signaling machinery. Moreover the kidney
is the major physiological target organ for aldosterone. Through
MR, aldosterone stimulated Mg2+ inﬂux in cells containing an intact
WT hTRPM7 system as well as in cells deﬁcient in TRPM7 α-kinase ac-
tivity. These data indicate that aldosterone/MR regulates Mg2+ trans-
port and [Mg2+]i in a TRPM7 channel-dependent, kinase-independent
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were stimulated with 100 nM aldosterone for short (1, 5, and 30 min) or long term (4, 8, and 24 h). Cell membrane and cytosol were fractionated. Line graphs, effects of aldoste-
rone on annexin-1 (A, B) and calpain-II (C, D) translocation from the cytosol to the cell membrane. Translocation was determined by the protein expression ratio in membrane to
cytosol fractions. Top panels, representative immunoblots of annexin-1 and calpain-II. Results are expressed as mean ± S.E. (% of vehicle) of 5 independent experiments. *p b 0.05
versus vehicle; ** p b 0.05 versus corresponding stimulation time in HEK-293 cells expressing WT hTRPM7.
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2170 A. Yogi et al. / Cellular Signalling 25 (2013) 2163–2175manner, since inactivation or deletion of the kinase domain did not in-
ﬂuence aldosterone-inducedMg2+ responses.While some studies sug-
gested that a functioning α-kinase domain is necessary for TRPM7-
mediated Mg2+ inﬂux [15,31], others have shown that the α-kinase
domain is not required, [12,32, reviewed in 33,34] a ﬁnding that we0
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Δ Kinaseconﬁrm here. The aldosterone concentration that we studied is higher
than that in plasma, but may reﬂect the elevated concentration of
local aldosterone at the tissue level, especially in pathological condi-
tions, such as in hypertension and kidney disease [35,36]. Accordingly,
the doses examined in our study may have pathophysiological signiﬁ-
cance. Moreover, most in vitro studies examine aldosterone in the
nanomolar range [2–4].
Associated with the rapid Mg2+ effect by aldosterone, was an in-
crease in ROS generation, due in large part to activation of NADPH ox-
idase as evidenced by increased cytosol-to-membrane translocation
of p47phox, and enhanced NADPH oxidase-driven ROS formation.
Aldosterone-induced activation of NADPH oxidase has previously
been demonstrated in kidney and vascular cells [37–40]. Functionally
aldosterone-induced ROS generation is associated with cellular
growth, migration and secretion, through pathways that involve
Ca2+, MAPK and activation of transcription factors, processes that
are Mg2+-sensitive. Here we show that NADPH oxidase regulation
by aldosterone involves TRPM7, but not TRPM7 α-kinase, a phenom-
enon similar to that for [Mg2+]i regulation. TRPM7 kinase has been
shown to modulate the Mg2+ sensitivity of the channel [12]. Accord-
ingly, the rapid aldosterone-induced Mg2+ and ROS responses may
rely primarily on TRPM7 channel activation. This is further supported
by the ﬁndings that 2-APB abrogated [Mg2+]i effects of aldosterone.
Such dissociation of the kinase from the ion-conducting pore has
been shown to be important in Fas-induced apoptosis, cell survival
and cell stress, phenomena that involve Mg2+ and ROS [41]. Although
we can not establish the interdependencies of TRPM7-regulated
Mg2+ and ROS in our paradigm, we have previously shown that
Mg2+ inﬂuences ROS generation [10,11] and there is growing evi-
dence that Mg2+ modulates ROS levels via NADPH oxidase as well
as through mitochondria and increased glutathione transferase activ-
ity [42,43]. These phenomena, through TRPM7 channel, may link di-
valent cations and ROS signaling, important in cell regulation.
Among the best characterized downstream signaling targets for
TRPM7 are annexin-1 and calpain-II, which have diverse cellular
functions [44]. Annexin-1, implicated in cell proliferation and differ-
entiation, is characteristically associated with anti-inﬂammatory re-
sponses [45], mediated in part through inhibition of MAP kinases
[46]. In WT hTRPM7 cells, activation of annexin-1 as assessed by
membrane translocation, was signiﬁcantly increased by aldsoterone.
This response, which was rapid, occurring within minutes, was abro-
gated by deletion of the α-kinase domain or a point mutation that
renders the α-kinase catalytically inactive. Since annexin-1 regulates
anti-inﬂammatory signaling, in part through interference with MAP
kinases, decreased activation in the context of down-regulated
α-kinase may promote inﬂammation [47].
α-Kinase was also involved in calpain-II signaling by aldosterone, be-
cause calpain translocation and spectrin cleavage were inhibited in
TRPM7α-kinase-deﬁcient/inactivated cells. Calpain-II, a Ca2+-dependent
protease, has been implicated in apoptosis and cell growth [48] and is
inﬂuenced by aldosterone, since spironolactone, aMRblocker, inhibited
cardiac remodeling in a model of atrial ﬁbrillation [49]. In line with the
effects on cell growth, TRPM7 α-kinase-regulated calpain-II activation
by aldosterone was not acute, but occurred over hours, suggestingFig. 5. Aldosterone-induced spectrin cleavage, a speciﬁc downstream target of calpain-II,
is blunted in HEK-293 cells expressing ΔKinase and K1648R hTRPM7 mutants. HEK-293
cells expressing WT hTRPM7 channels or the mutants ΔKinase (deleted kinase) and
K1648R (inactive kinase) were stimulated with 100 nM aldosterone (4, 8 and 24 h) in
the absence or presence of the MR antagonist eplerenone (10 μM). (A) Line graph, effect
of aldosterone on spectrin cleavage, deﬁned as the ratio of cleaved spectrin to intact
spectrin. (B) Bar graph, effect of eplerenone on aldosterone-induced spectrin cleavage in
WT hTRPM7. GAPDH was used as loading control. Results are expressed as % of vehicle
(mean ± S.E.) of 5 independent experiments. Top panels, representative immunoblots
of spectrin, cleaved spectrin, and GAPDH. *p b 0.05 versus vehicle; ** p b 0.05 versus cor-
responding stimulation time in HEK-293 cells expressing WT hTRPM7; †p b 0.05 versus
corresponding stimulation time in the absence of eplerenone.
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Fig. 6. Aldosterone induces MAPKs phosphorylation in ΔKinase and K1648R but not in WT hTRPM7 cells. HEK-293 cells expressing WT hTRPM7 channels or the mutants ΔKinase
(deleted kinase) and K1648R (inactive kinase) were stimulated with 100 nM aldosterone (1–60 min). Line graphs, effect of aldosterone on (A) p38MAPK, (B) SAPK/JNK MAPK, and
(C) ERK1/2 MAPK phosphorylation. Results are expressed as % of vehicle (mean ± S.E.) of 7 independent experiments. Side panels, representative immunoblots of p38MAPK
[Thr180/Tyr182], p38MAPK, SAPK/JNK MAPK [Thr183/Tyr185], SAPK/JNK MAPK, ERK1/2 MAPK [Thr202/Tyr204], ERK1/2 MAPK. *p b 0.05 versus corresponding stimulation time in
HEK-293 cells expressing WT hTRPM7.
2171A. Yogi et al. / Cellular Signalling 25 (2013) 2163–2175probable genomic signaling and de novo protein synthesis. These differ-
ential kinetic responses indicate that aldosterone/MR signaling via
TRPM7 is highly regulated through, as yet, unknown intermediaries.
To further investigate molecular processes associated with
TRPM7 signaling by aldosterone, we focused on MAP kinases, master
signaling molecules typically associated with inﬂammation and cell
stress [50]. Aldosterone induced a signiﬁcant increase in activation
of ERK1/2, p38MAPK and SAPK/JNK in cells in which TRPM7
α-kinase domain was absent or inactive, but not in cells in which
WT hTRPM7 was intact. Similar patterns were observed for theproinﬂammatory proteins ICAM-1, PAI-1 and Cox2, which are down-
stream of MAP kinases.
To interrogate in greater detail the potential role of TRPM7 channel
in inﬂammatory processes associated with TRPM7 α-kinase, we ex-
posed wild-type and TRPM7 α-kinase-deﬁcient cells 2-APB, a TRPM7
channel inhibitor. 2-APB augmented activation of pro-inﬂammatory
MAP kinases (p38MAP kinase and JNK), effects that were associated
with increased expression of pro-inﬂammatory mediators (Cox-2 and
ICAM-1). Considering that 2-APB blocked aldosterone-induced Mg2+
inﬂuxwithout inhibiting pro-inﬂammatory signaling, itmay bepossible
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Fig. 7. Aldosterone induces increase of ICAM-1, Cox-2 and PAI-1 protein expression in ΔKinase and K1648R but not in WT hTRPM7 cells. HEK-293 cells expressing WT hTRPM7
channels or the mutants ΔKinase (deleted kinase) and K1648R (inactive kinase) were stimulated with 100 nM aldosterone (4, 8 and 24 h). Line graphs, effect of aldosterone on
(A) ICAM-1, (B) Cox-2, and (C) PAI-1 protein expression. GAPDH was used as loading control. Results are expressed as % of vehicle (mean ± S.E.) of 7 independent experiments.
Side panels, representative immunoblots of ICAM-1, Cox-2, PAI-1, and GAPDH. *p b 0.05 versus corresponding stimulation time in HEK-293 cells expressing WT hTRPM7.
2172 A. Yogi et al. / Cellular Signalling 25 (2013) 2163–2175that TRPM7 channel-related changes in [Mg2+]i are dissociated from in-
ﬂammatory responses induced by aldosterone, whichmight be regulat-
ed primarily by the α-kinase. In further support of this, 2-APB did not
signiﬁcantly alter aldosterone-induced activation of pro-inﬂammatory
signaling pathways nor expression of Cox-2 and ICAM-1 in cells lacking
functional α-kinase. These ﬁndings have a number of implications.
Firstly TRPM7 channel and TRPM7 α-kinase have distinct molecular
functions that may not be interdependent, and secondly, TRPM7
α-kinase downregulation promotes inﬂammation by aldosterone
suggesting that TRPM7α-kinasemay negatively regulate inﬂammatory
signaling. These ﬁndings are in line with our observations thatactivation of the anti-inﬂammatory protein annexin-1 was blunted in
TRPM7 α-kinase-deﬁcient cells. A link between anti-inﬂammatory ef-
fects of annexin-1 and decreased MAP kinase activation has previously
been reported [47]. We speculate that aldosterone may inﬂuence in-
ﬂammation by inhibiting α-kinase activity. This however remains to
be demonstrated.
5. Conclusions
Our study has identiﬁed novel mechanisms for aldosterone signal-
ing through TRPM7 kinase-dependent and -independent pathways.
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Fig. 8. Effects of 2-APB on aldosterone-induced activation of pro-inﬂammatory MAP kinases, p38MAP kinase and JNK, in WT hTRPM7, ΔKinase and K1648R cells. HEK-293 cells ex-
pressing WT hTRPM7 channels (A, D) or the mutants ΔKinase (deleted kinase) (B, E) and K1648R (inactive kinase) (C, F) were stimulated with 100 nM aldosterone (1–30 mins) in
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*p b 0.05; **p b 0.01 versus control.
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2175A. Yogi et al. / Cellular Signalling 25 (2013) 2163–2175Whereas aldosterone stimulates Mg2+ inﬂux, NADPH oxidase activity
and superoxide anion production in a TRPM7 channel sensitive,
kinase-insensitive manner, activation of annexin-1 and calpain de-
pend on TRPM7 α-kinase. Moreover, TRPM7 α-kinase may play an
important role in modulating inﬂammatory responses by aldosterone.
Our results identify new molecular mechanisms for aldosterone sig-
naling that involve MR-activated TRPM7/TRPM7 α-kinase, mediated,
in part, through non-genomic processes. Such phenomena could con-
tribute to the pleiotropic actions of aldosterone, especially those asso-
ciated with cellular divalent cation transport and pro-inﬂammatory
signaling.
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